spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Aridhia broadens European appeal with new RSRCH Health service in Netherlands

Aridhia

Aridhia, Vancis and MGRID announce the expansion of their partnership

Scottish clinical and translational informatics company Aridhia, Netherlands-based ICT service provider Vancis, and clinical datasets experts MGRID are today announcing the expansion of their existing partnership with the launch of a new research platform service, RSRCH-Health, into the Netherlands.

The initiative will be introduced at the Health-RI conference on December 1st in Amersfoort, Netherlands to an audience of researchers, academics and clinicians who are being encouraged to work together to enable ground-breaking biomedical research.

The growth of Aridhia’s operations outside the UK follows the partnership agreement with Vancis announced in mid-2015. A number of new jobs in both Scotland and the Netherlands are expected to be created as a result of this collaboration.

Based on Aridhia’s AnalytiXagility data analysis platform, RSRCH-Health was first established in early 2016 to deliver a digital research environment to Radboudumc Nijmegen in a three-year deal, making it the first University Medical Centre in the Netherlands to offer a digital platform to all research teams across the institution.

Radboudumc is currently rolling out RSRCH-Health across the entire organisation, providing analytical workspaces for up to 1600 research projects to accelerate the delivery of research studies into clinical practice.

The extended Vancis, Aridhia, and MGRID collaboration - which goes by the name RSRCH - signifies continued growth for Aridhia, one of Scotland’s data science success stories.

Chris Roche, Aridhia’s CEO, said of the new company: “The development of AnalytiXagility into a tailored offering for the Netherlands’ market is very exciting for Aridhia and is validation that our platform is precisely what research-driven organisations need to achieve the best outcomes.

“Research teams worldwide are realising the value in wide-scale collaboration around data, and together with Vancis and MGRID, we believe that RSRCH-Health represents an answer to the data challenges that they face.”

Eli Berkelmans, RSRCH Managing Director said: “RSRCH-Health gives us the means to deliver a unique on-demand, secure platform service specifically catering to the needs of researchers.

“It is already being used at Radboudumc by a number of showcase projects and thanks to word-of-mouth, it is generating interest across Europe. We’re excited about the opportunities this opens up to us and, more importantly, to research teams worldwide.”

The RSRCH-Health platform incorporates Aridhia’s existing AnalytiXagility services with infrastructure expertise from Vancis, and MGRID’s Aperture which speeds up creation of datasets for clinical research, to deliver a self-service capability which answers the specific requirements of the Netherland’s market.

Developed to deliver rapid change by enabling a multidisciplinary, collaborative approach to biomedical research, RSRCH-Health is available via the Amsterdam based RSRCH team and is suitable for individual studies, or as the digital environment for all projects within a research-driven institution.

This partnership adds to Aridhia’s growing portfolio of European projects as it exports AnalytiXagility to prominent research collaborations across the continent, including the ground-breaking European Prevention of Alzheimer’s Dementia (EPAD) project, an Innovative Medicines Initiative funded research programme.
phone 00 44 131 560 1470
web www.aridhia.com/
email Hobart House, 80 Hanover Street, Edinburgh, EH2 1EL
 
Print this page
Send to a friend
   
spacer
News and Press Releases

World-leading cancer stem cell expert joins Avacta Scientific Advisory Board

Developer of biotherapeutics and research reagents announces the appointment of Professor Gerard Evan to its Scientific Advisory Board
More info >>


White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

12th annual Cold Chain Distribution Conference and Exhibition

13-14 December 2017, Copthorne Tara Hotel, London, UK

Responding to the evolution within the industry, SMi is proud to announce the return of its leading 12th annual Cold Chain Distribution event. Returning to London in December, this year's event will remain at the forefront of innovation
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement